FindTrial
Sign In

Medium Dose of Cytarabine and Mitoxantrone

The Clinical Observationg on HAM for Acute Myeloid Leukemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04024241
Acronym
HAM
Enrollment
250
Registered
2019-07-18
Start date
2017-09-01
Completion date
2019-08-31
Last updated
2019-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myelogenous Leukemia, Chemotherapy

Keywords

AML HAM

Brief summary

By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.

Detailed description

The patients of AML in shenzhen people's hospital were randomly divided into two therapy groups.One group was treated by High dose of cytarabine ,and the other was HAM.Evaluate the two chemotherapy schemes by bone marrow suppression time and patient survival time.

Interventions

DEVICEFlow Cytometer

high dose

DRUGMitoxantrone

high dose

DRUGCytarabine

high dose

Sponsors

Shenzhen People's Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
14 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

people diagnosed as AML

Exclusion criteria

* acute promyeloytic leukemia

Design outcomes

Primary

MeasureTime frameDescription
bone marrow suppression timeone monthtime of agranulocytosis
patient survival timethree yearsdisease free survival

Countries

China

Contacts

Primary ContactYixuan Cao, master
358521758@qq.com15813880801

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026